Fortress Biotech FBIOP 深沪

等待开盘 12-16 09:30:00 美东时间

9.50

+1.792

+23.25%

华盛通

立即下载

最高9.67
今开8.17
成交量 8.31万股
最低 8.10
昨收 7.7079
总市值 3255.75万
52周最高 9.845
市盈率 ^静 --
换手率 2.43%
52周最低 4.72
委比 -52.02%
总股本 342.71万
历史最高 20.5506
量比 4.71
振幅 20.37%
历史最低 -1.5766
每手 1
风险率 0.96%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

Fortress Biotech Amends Credit Agreement with Oaktree

Fortress Biotech ( ($FBIO) ) has shared an announcement. On December 12, 2025, ...

今天 06:45
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Journey Medical Corporation announced positive results from a Phase 1 clinical trial of Emrosi, a low-dose oral minocycline for rosacea. The trial met all primary objectives, showing no significant impact on skin, GI tract, or vaginal microbiota, and no safety issues over 16 weeks. Emrosi is FDA-approved for treating inflammatory lesions in adults. The study, published in the Journal of Drugs in Dermatology, supports its long-term use and safety ...

12-10 13:30
Fortress Biotech Q3 EPS $0.11 Beats $(0.42) Estimate, Sales $17.631M Miss $21.018M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.42) by 126.19 percent. This is a 114.47 percent increase over losses of $(0.76) per share

11-14 21:43
Fortress Biotech Q3 Earnings Preview

Fortress Biotech (FBIO) is scheduled to announce Q3 earnings results on Wednesday, November 12th, after market close. The consensus EPS Estimate is -$0.63 and the consensus Revenue Estimate is $21.02M...

11-12 06:35
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Avenue Therapeutics and its subsidiary Baergic Bio have agreed to be acquired by Axsome Therapeutics for up to $82 million in potential milestones and royalties. The acquisition includes global rights to BAER-101, a novel epilepsy treatment, now to be known as AXS-17. Avenue expects to receive approximately 74% of future payments and royalties under the agreement. Baergic shareholders are eligible for up to $79 million in sales-based milestones a...

11-06 12:00
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Journey Medical Corporation will release its third quarter 2025 financial results after U.S. markets close on November 12, 2025. A conference call and audio webcast will be held on the same day at 4:30 p.m. ET. Interested parties can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join, or access the webcast via the company’s website. A replay will be available for 30 days. The company focuses on selling and marketing FDA-appr...

11-05 13:30
Fortress Biotech Receives FDA Response on CUTX-101

Fortress Biotech ( ($FBIO) ) has shared an announcement. On October 1, 2025, Fo...

10-01 21:19
Fortress Biotech plunges as FDA rejects rare disease drug

Fortress Biotech (NASDAQ:FBIO) fell ~31% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve CUTX-101, a treatment developed by the company and its Indi...

10-01 20:59
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket

Shares of Ryvyl Inc (NASDAQ:RVYL) rose sharply in pre-market trading after the ...

10-01 17:45
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Shares of Docusign Inc (NASDAQ:DOCU) rose sharply in pre-market trading after t...

09-05 17:20

派息除权日	每股总股息	派息日期
2024-06-14	0.20	2024-06-30
2024-05-14	0.20	2024-05-31
2024-04-12	0.20	2024-04-30
2024-03-14	0.20	2024-03-31
2024-02-14	0.20	2024-02-29
2024-01-11	0.20	2024-01-31
2023-12-14	0.20	2023-12-31
2023-11-14	0.20	2023-11-30
2023-10-12	0.20	2023-10-31
2023-09-14	0.20	2023-09-30
2023-08-14	0.20	2023-08-31
2023-07-13	0.20	2023-07-31
2023-06-14	0.20	2023-06-30
2023-05-12	0.20	2023-05-31
2023-04-13	0.20	2023-04-30
2023-03-14	0.20	2023-03-31
2023-02-14	0.20	2023-02-28
2023-01-12	0.20	2023-01-31
2022-12-14	0.20	2022-12-31
2022-11-14	0.20	2022-11-30
2022-10-13	0.20	2022-10-31
2022-09-14	0.20	2022-09-30
2022-08-12	0.20	2022-08-31
2022-07-14	0.20	2022-07-31
2022-06-14	0.20	2022-06-30
2022-05-12	0.20	2022-05-31
2022-04-13	0.20	2022-04-30
2022-03-14	0.20	2022-03-31
2022-02-14	0.20	2022-02-28
2022-01-13	0.20	2022-01-31
2021-12-14	0.20	2021-12-31
2021-11-12	0.20	2021-11-30
2021-10-14	0.20	2021-10-30
2021-09-14	0.20	2021-09-30
2021-08-12	0.20	2021-08-30
2021-07-14	0.20	2021-07-30
2021-06-14	0.20	2021-06-30
2021-05-13	0.20	2021-05-30
2021-04-14	0.20	2021-04-30
2021-03-12	0.20	2021-03-31
2021-02-11	0.20	2021-02-28
2021-01-14	0.20	2021-01-31
2020-12-14	0.20	2020-12-31
2020-11-12	0.20	2020-11-30
2020-10-14	0.20	2020-10-31
2020-09-14	0.20	2020-09-30
2020-08-20	0.20	2020-08-31
2020-07-17	0.20	2020-07-31
2020-06-12	0.59	2020-06-30
2020-03-13	0.59	2020-03-31
2019-12-12	0.59	2019-12-31
2019-09-12	0.59	2019-09-30
2019-06-13	0.59	2019-07-01
2019-03-14	0.59	2019-03-31
2018-12-13	0.59	2018-12-31
2018-09-13	0.59	2018-09-30
2018-06-14	0.59	2018-06-30
2018-03-14	0.59	2018-03-30

公司名称	Fortress Biotech, Inc.
行业分类	Pharmaceuticals: Major
业务描述	Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech FBIOP 深 沪

9.50

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

Fortress Biotech FBIOP 深沪